Study results highlight the Company’s Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform for characterization of Alzheimer’s Disease
PALO ALTO, Calif., Dec. 14, 2020 /PRNewswire/ — Molecular Stethoscope, Inc., a precis… […]
SAN DIEGO, Dec. 6, 2020 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cance… […]
Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile
SAN DIEGO, Dec. 5, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ:PSTX),… […]
Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile
SAN DIEGO, Dec. 5, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ:PSTX),… […]
– Disease control observed in 92% of patients- Conference call to be held today at 2:30pm PT
SAN DIEGO, Nov. 11, 2020 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated … […]
SAN DIEGO, Nov. 2, 2020 /PRNewswire/ — In a case study released October 23 by Oculus for Business from Facebook, Nimbus Therapeutics explains why they expect to save tens of thousands of dollars per year by investing in virtual reality (VR) hardwar… […]
— Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating init… […]
– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]
SAN DIEGO, Oct. 6, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIOTM ), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharm… […]
– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –
SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]
Copyright © 2021 Biotech Networks, LLC
